Reckitt Benckiser Group (RB) PT Set at GBX 5,500 by Credit Suisse Group

Reckitt Benckiser Group (LON:RB) has been assigned a GBX 5,500 ($71.20) target price by investment analysts at Credit Suisse Group in a research note issued on Thursday, July 19th. The brokerage presently has a “sell” rating on the stock. Credit Suisse Group’s price objective suggests a potential downside of 19.34% from the stock’s current price.

Other equities analysts have also issued research reports about the company. Societe Generale set a GBX 6,500 ($84.14) price target on Reckitt Benckiser Group and gave the company a “buy” rating in a research note on Thursday, March 22nd. Liberum Capital reaffirmed a “buy” rating and issued a GBX 7,400 ($95.79) price objective on shares of Reckitt Benckiser Group in a research report on Thursday, March 22nd. Deutsche Bank reaffirmed a “buy” rating on shares of Reckitt Benckiser Group in a research report on Friday, March 23rd. JPMorgan Chase & Co. set a GBX 7,200 ($93.20) price objective on Reckitt Benckiser Group and gave the company a “buy” rating in a research report on Wednesday, March 28th. Finally, Sanford C. Bernstein set a GBX 8,100 ($104.85) price objective on Reckitt Benckiser Group and gave the company a “buy” rating in a research report on Monday, April 23rd. Three equities research analysts have rated the stock with a sell rating, ten have given a hold rating and ten have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average target price of GBX 6,992.86 ($90.52).

RB traded down GBX 60 ($0.78) on Thursday, hitting GBX 6,819 ($88.27). The company had a trading volume of 913,376 shares, compared to its average volume of 1,720,000. Reckitt Benckiser Group has a 1-year low of GBX 5,562 ($72.00) and a 1-year high of GBX 8,110.43 ($104.99).

In related news, insider Christopher Sinclair bought 809 shares of the company’s stock in a transaction on Friday, May 25th. The shares were acquired at an average cost of GBX 6,030 ($78.06) per share, for a total transaction of £48,782.70 ($63,149.13).

Reckitt Benckiser Group Company Profile

Reckitt Benckiser Group plc manufactures, markets, and sells health, hygiene, and home products. The company offers products for the treatment of analgesic and gastro-intestinal problems, sore throat, cough, pain, and flu, as well as wellness products in sexual wellbeing, footcare, vitamins, and supplements under the Durex, Gaviscon, Nurofen, Mucinex, Scholl/Amopé, and Strepsils brand names.

Featured Story: Book Value Per Share – BVPS

Analyst Recommendations for Reckitt Benckiser Group (LON:RB)

Receive News & Ratings for Reckitt Benckiser Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reckitt Benckiser Group and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply